Pelthos Therapeutics Inc. (PTHS) - Dilution Analysis

10-Q filing | 3.3M shares outstanding

10-K filing | 3.4M shares outstanding

8-K filing: Pelthos Therapeutics Inc. entered into a Venture Loan and Security Agreement with Horizon Technology Finance Corporation and issued warrants to purchase up to 65,488 shares of common stock at an exercise price of $27.49 per share.

10-Q filing | 3.1M shares outstanding

S-3/A filing: Primary offering of securities of the undersigned registrant pursuant to this registration statement.

S-3 filing: This S-3 filing relates to the resale of up to 8,137,868 shares of common stock of Pelthos Therapeutics Inc. by selling stockholders.

10-Q filing | 3.0M shares outstanding

8-K filing: Pelthos Therapeutics, Inc. completed a private placement (PIPE Financing) of Series A Preferred Stock, converted a portion of the Series A Preferred Stock into Common Stock, and effected a 1-for-10 reverse stock split. ($50.1M proceeds)

10-Q filing | 6.1M shares outstanding

8-K filing: Channel Therapeutics Corporation enters into a merger agreement with LNHC, Inc. and certain investors, pursuant to which the PIPE Investors have agreed to subscribe for and purchase in cash an aggregate of approximately 50,100 of shares of Series A Preferred Stock, at a price per share equal to $1,000. ($50.1M proceeds)

10-K filing | 5.6M shares outstanding

POS AM filing: The filing is an amendment to the original registration statement related to the proposed sale of 4,069,823 shares of common stock, including IPO shares, selling stockholder shares, and shares issuable upon exercise of a warrant.

POS AM filing: This POS AM filing relates to the proposed sale of an aggregate of 4,069,823 shares of Common Stock, consisting of (i) 1,100,000 shares of Common Stock (the "IPO Shares") and (ii) 2,969,823 shares of Common Stock (the "Selling Stockholder Shares") on behalf of certain selling stockholders, as well as the issuance of a warrant to the representative of the underwriters exercisable for 55,000 shares of Common Stock.

POS AM filing: This POS AM filing describes the reincorporation of a company where outstanding shares of common and preferred stock were converted to shares of the registrant, and options, rights and warrants were converted to acquire an equal number of shares of the registrant's common stock.

10-Q filing | 5.8M shares outstanding

10-Q filing | 5.8M shares outstanding

S-1 filing: This S-1 filing registers shares of common stock for resale related to a committed equity financing facility with Tikkun, where Tikkun may purchase up to $30 million of common stock at the company's discretion.

10-Q filing | 5.8M shares outstanding

10-K filing | 5.9M shares outstanding

8-K filing: Chromocell Therapeutics Corporation completed an initial public offering (IPO) of 1,100,000 shares of common stock at $6.00 per share and a 1-for-9 reverse stock split became effective. ($6.6M proceeds)

S-1/A filing: This S-1/A filing registers 4,009,480 shares of common stock for an IPO, including shares for sale by the company and selling stockholders, as well as shares underlying the Representative's Warrants; it also proposes an equity line of credit (ELOC) following the IPO.

S-1/A filing: This S-1/A filing registers shares of common stock for an initial public offering, resale by selling stockholders, shares underlying representative's warrants, shares for promissory notes, and an equity line of credit.

S-1/A filing: This S-1/A filing registers the initial public offering of Chromocell Therapeutics Corporation, including shares offered by the company and shares offered by selling stockholders, as well as shares underlying the representative's warrants, and describes a proposed equity line of credit

S-1/A filing: This S-1/A filing registers 1,039,657 shares of common stock for sale by the company in an IPO, 3,080,953 shares of common stock for resale by selling stockholders, and shares of common stock underlying the Representative's Warrants.

S-1/A filing: This S-1/A filing registers the initial public offering of Chromocell Therapeutics Corporation, consisting of 1,038,674 shares of common stock and 2,909,353 shares of common stock being offered by selling stockholders, as well as shares of common stock underlying the Representative's Warrants.

S-1/A filing: Chromocell Therapeutics Corporation is offering 2,109,130 shares of common stock in an initial public offering with an assumed price of $3.75 per share, while certain selling stockholders are offering 2,686,554 shares of common stock.

S-1/A filing: This S-1/A filing registers shares of common stock for an IPO, including shares for sale by the company and selling stockholders, as well as shares underlying representative's warrants.

S-1/A filing: This S-1/A filing is for the initial public offering of Chromocell Therapeutics Corporation, registering 1,741,008 shares of common stock for sale by the company and 2,686,554 shares of common stock for resale by selling stockholders.

S-1/A filing: This S-1/A filing registers shares of common stock for an IPO, shares of common stock underlying the Representative's Warrants and Advisor Warrants, and shares of common stock offered by selling stockholders.

S-1/A filing: This S-1/A filing includes information on Series B Convertible Redeemable Preferred Stock, underwriter warrants issued to Maxim Group LLC and A.G.P./Alliance Global Partners, and Senior Secured Convertible Promissory Notes with associated warrants.

S-1/A filing: The filing is an amended S-1 registration statement for an initial public offering of units, each consisting of one share of common stock and one warrant. It also covers the resale of common stock by selling stockholders and potential issuance of shares upon exercise of warrants.

S-1/A filing: This S-1/A filing relates to a potential initial public offering, including the issuance of common stock, warrants, and units, as well as the conversion of preferred stock and notes. It also discusses representative and advisor warrants.

S-1/A filing: This S-1/A filing includes information about common stock, blank check preferred stock, Series A convertible preferred stock, 2023 Equity Incentive Plan, and promissory notes.